Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Parkinson disease”

Cross-System Effects of Acute Intermittent Hypercapnia-Based Interventions in PDRecruiting
NCT07674264NAUpdated Aug 21, 2026
Sponsor: University of Florida
Parkinson Disease · Parkinsonism
United States
Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System AtrophyCompleted
NCT06671938Phase 2Updated Aug 21, 2026
Sponsor: BioArctic AB
Parkinson Disease · Multiple System Atrophy
Poland, Spain
STN-tTIS With Different Intervention Intervals Versus Standard Medical Treatment for Parkinson's DiseaseRecruiting
NCT07774312NAUpdated Aug 21, 2026
Sponsor: Ruijin Hospital
Parkinson's Disease (PD)
China
Combined Genome and RNA Sequencing for Genetic Diagnosis of ParkinsonismRecruiting
NCT06576713NAUpdated Aug 21, 2026
Sponsor: University Hospital, Strasbourg, France
Parkinson's Disease
France
Genetics and Aerobic Exercise to Slow Parkinson's Disease TrialRecruiting
NCT06442033NAUpdated Aug 21, 2026
Sponsor: Jay Alberts
Parkinson Disease
United States
Telehealth in Lewy Body DementiaActive Not Recruiting
NCT05014971NAUpdated Aug 20, 2026
Sponsor: University of Florida
Lewy Body Dementia With Behavioral Disturbance · Lewy Body Parkinson Disease · Lewy Body Disease
United States
Hereditary Parkinson s Disease Natural History ProtocolCompleted
NCT02511015N/AUpdated Aug 20, 2026
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Parkinson Disease 6, Early-Onset · Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human · Parkinson Disease Autosomal Recessive, Early Onset · Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1
United States
Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCCNot Yet Recruiting
NCT07776340Phase 2Updated Aug 20, 2026
Sponsor: Fudan University
HPV-unrelated Head and Neck Squamous Cell Carcinoma
China
Personalized Real-Time DBS and PD MechanismsRecruiting
NCT06013956Phase 4Updated Aug 20, 2026
Sponsor: David Escobar
Parkinson Disease
United States
French Parkinson's Disease Cohort - NS-PARKRecruiting
NCT04888364N/AUpdated Aug 20, 2026
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Parkinson Disease
France
Adaptive Neurostimulation to Restore Sleep in Parkinson's DiseaseCompleted
NCT04620551NAUpdated Aug 20, 2026
Sponsor: University of Nebraska
Parkinson Disease · Sleep Fragmentation
United States
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension StudyActive Not Recruiting
NCT05899049Phase 3Updated Aug 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
China
Exploring the Efficacy of the Effortful Swallow Maneuver for Improving Swallowing in People With PDNot Yet Recruiting
NCT07773025NAUpdated Aug 19, 2026
Sponsor: University of Alberta
Dysphagia · Parkinson Disease (PD)
Pimavanserin vs. Quetiapine for Treatment of Parkinson's PsychosisRecruiting
NCT04373317Phase 4Updated Aug 19, 2026
Sponsor: VA Office of Research and Development
Parkinson's Disease Psychosis
United States
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)Completed
NCT03740165Phase 3Updated Aug 19, 2026
Sponsor: Merck Sharp & Dohme LLC
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
United States, Australia, Belgium, Brazil, Canada +17 more
Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients.Withdrawn
NCT05931484Phase 2Updated Aug 19, 2026
Sponsor: Forest Hills Lab
Parkinson Disease
A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.Recruiting
NCT07630545Phase 1Updated Aug 19, 2026
Sponsor: Mission Therapeutics
Parkinson's Disease (PD) · Mild to Moderate Parkinson's Disease · Early Stage Parkinson's Disease
Australia, France, Germany, United Kingdom
The Validity and Reliability of an Improved Paper Grasping Test for Parkinson's DiseaseCompleted
NCT07772622N/AUpdated Aug 19, 2026
Sponsor: Sanko University
Parkinson's Disease · Validity · Reability
Turkey (Türkiye)
Research Into the Expression of the csgA-gene and How it Changes in Patients With Parkinson's DiseaseRecruiting
NCT07175922N/AUpdated Aug 19, 2026
Sponsor: Vertero Therapeutics
Parkinsons Disease (PD)
Netherlands
Bracing for Walking in Parkinson's DiseaseCompleted
NCT03192046NAUpdated Aug 18, 2026
Sponsor: University of Texas Southwestern Medical Center
Gait Disorders, Neurologic · Parkinson Disease
United States
Home-Based Exercise Programs for Fall Prevention in Parkinson DiseaseCompleted
NCT07590700NAUpdated Aug 18, 2026
Sponsor: Uludag University
PARKINSON DISEASE (Disorder) · Falls Prevention · Exercise
Turkey (Türkiye)
Evaluation and Treatment of Neurosurgical DisordersRecruiting
NCT00060541N/AUpdated Aug 18, 2026
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Neurologic Disorders
United States
A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's DiseaseRecruiting
NCT07322887Phase 2Updated Aug 17, 2026
Sponsor: GEN İlaç ve Sağlık Ürünleri A.Ş.
Parkinson's Disease (PD)
Netherlands
Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)Recruiting
NCT06482268Phase 1Updated Aug 17, 2026
Sponsor: University of California, San Diego
PD - Parkinson's Disease
United States
Neuromodulation for Patients With Parkinson's DiseaseNot Yet Recruiting
NCT07767006NAUpdated Aug 17, 2026
Sponsor: Felipe Fregni, MD, PhD, MPH
Adults With Parkinson's Disease
United States

Previous page Next page